News

Quotient Sciences Appoints Thierry Van Nieuwenhove as CEO

Read Now
Press enter to search

Suggested searches

Early Development
Candidate Selection
Late Development
ADME
Translational Pharmaceutics

News

News
Quotient Sciences Appoints Thierry Van Nieuwenhove as CEO
Quotient Sciences announces the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16th October 2023. Thierry succeeds Mark Egerton who retires after 18 years as CEO with Quotient Sciences. As part of the leadership transition, the Company also announces that Wayne Hewett has been appointed as Non-Executive Chairman.
Reset filters
6 / 115 articles
Quotient Sciences supports Phase 1 clinical trial of novel obesity therapy with Gubra
Gubra announces that the first human subject has been dosed with a new long-acting amylin agonist (GUBamy) as a potential treatment for obesity. This first clinical trial is being conducted with Quotient Sciences.
News
Quotient Sciences supports Medivir with updated formulation of fostrox
Quotient Sciences has partnered with Medivir recently with formulation development and drug product manufacturing of fostroxacitabine bralpamide (fostrox).
Awards
Quotient Sciences Recognized in the Pharma Innovation Awards 2023
The Pharma Innovation Awards 2023 recognizes Quotient Sciences’ FlowInova platform with an award for its ability to streamline the scale-up process for early-phase API development.
Awards
Quotient Sciences Recognized in the 2023 British Made Awards
Quotient Sciences is one of the 2023 winners of the SME British Made Awards.
Article
Outsourcing Pharma: Paul Quigley on going with the flow in drug substance manufacturing
In a conversation with Outsourcing Pharma at CPHI Barcelona, Paul Quigley, principal research fellow of drug substance at Quotient Sciences, explained how continuous flow manufacturing is taking off in the production of active pharmaceutical ingredients (APIs).
Growth
Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand
Recent investment in the sterile fill/finish capabilities at Quotient Sciences' Alnwick, UK facility adds to the current capacity of the Annex 1 compliant facility to meet increasing industry demand for fully integrated drug development programs.